scholarly journals Interindividual Variability in Hepatic Expression of the Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2): Quantification by Liquid Chromatography/Tandem Mass Spectrometry

2012 ◽  
Vol 40 (5) ◽  
pp. 852-855 ◽  
Author(s):  
Anand K. Deo ◽  
Bhagwat Prasad ◽  
Larissa Balogh ◽  
Yurong Lai ◽  
Jashvant D. Unadkat
Keyword(s):  
Mass Spectrometry ◽  
Liquid Chromatography ◽  
Multidrug Resistance ◽  
Tandem Mass Spectrometry ◽  
Interindividual Variability ◽  
Tandem Mass ◽  
Hepatic Expression ◽  
Chromatography Tandem Mass Spectrometry ◽  
Liquid Chromatography Tandem Mass

scholarly journals Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)-Based Proteomics of Drug-Metabolizing Enzymes and Transporters

Molecules ◽  
2020 ◽  
Vol 25 (11) ◽  
pp. 2718
Author(s):  
Jiapeng Li ◽  
Hao-Jie Zhu
Keyword(s):  
Mass Spectrometry ◽  
Liquid Chromatography ◽  
Tandem Mass Spectrometry ◽  
Interindividual Variability ◽  
Drug Metabolizing Enzymes ◽  
Tandem Mass ◽  
Metabolizing Enzymes ◽  
Chromatography Tandem Mass Spectrometry ◽  
Liquid Chromatography Tandem Mass

Liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics is a powerful tool for identifying and quantifying proteins in biological samples, outperforming conventional antibody-based methods in many aspects. LC-MS/MS-based proteomics studies have revealed the protein abundances of many drug-metabolizing enzymes and transporters (DMETs) in tissues relevant to drug metabolism and disposition. Previous studies have consistently demonstrated marked interindividual variability in DMET protein expression, suggesting that varied DMET function is an important contributing factor for interindividual variability in pharmacokinetics (PK) and pharmacodynamics (PD) of medications. Moreover, differential DMET expression profiles were observed across different species and in vitro models. Therefore, caution must be exercised when extrapolating animal and in vitro DMET proteomics findings to humans. In recent years, DMET proteomics has been increasingly utilized for the development of physiologically based pharmacokinetic models, and DMET proteins have also been proposed as biomarkers for prediction of the PK and PD of the corresponding substrate drugs. In sum, despite the existence of many challenges in the analytical technology and data analysis methods of LC-MS/MS-based proteomics, DMET proteomics holds great potential to advance our understanding of PK behavior at the individual level and to optimize treatment regimens via the DMET protein biomarker-guided precision pharmacotherapy.

Sign in / Sign up

Export Citation Format

Share Document